0
Abstract: Slide Presentations |

LOW-MOLECULAR WEIGHT HEPARIN FOR DEEP VEIN THROMBOSIS PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS FREE TO VIEW

Andrew F. Shorr, MD*; William L. Jackson, MD; Brendan M. Weiss, MD; Lisa K. Moores, MD
Author and Funding Information

Washington Hospital Center, Washington, DC


Chest


Chest. 2005;128(4_MeetingAbstracts):192S-a-193S. doi:10.1378/chest.128.5_suppl_2.583S
Text Size: A A A
Published online

Abstract

PURPOSE:  Options for deep-vein thrombosis (DVT) prevention in medical patients include both unfractionated heparin (UFH) and low-molecular weight heparin (LMWH). Although more expensive than UFH, LMWHs are associated with fewer side-effects. We hypothesized that because of this, LMWH would prove cost-effective for DVT prevention in medical patients.

METHODS:  We modeled the cost and efficacy of UFH vs. LMWH for DVT prevention in a hypothetical cohort of 1,000 medically ill subjects. Model estimates were derived from published trials of DVT prophylaxis in this setting and from various meta-analyses describing rates of bleeding and heparin-induced thrombocytopenia (HIT). Costs of clinical events (e.g., DVT, bleeding, HIT) were taken from reports measuring the economic consequences of these outcomes. We used enoxaparin as the representative LMWH and biased the model against LMWH. We reduced literature based estimates of event rates by 20%, did not include fixed, pharmacy administration costs, and assumed that successful DVT prevention altered neither mortality nor quality of life. We performed multiple sensitivity analyses.

RESULTS:  In the base-case, enoxaparin had minimal impact on rates of either DVT or bleeding. However, the rate of HIT was reduced by 90% with LMWH. Despite its higher acquisition costs, use of enoxaparin led to net savings. Total costs (e.g., sum of acquisition costs for medications plus costs for treatment of DVT, bleeding, and HIT) were $405 per patient with UFH vs. $316 with LMWH (net savings $89, 95% CI: $7 to $373 by Monte Carlo simulation). Sensitivity analysis revealed the model to be moderately sensitive to the costs of HIT and the frequency of HIT. In a worst-case scenario (all inputs skewed against enoxaparin), routine use of the LMWH still resulted in savings.

CONCLUSION:  From a health system perspective, LMWHs are economically attractive for DVT prevention in medical patients. The impact of LMWHs on rates of HIT and bleeding more than balance their acquisition costs.

CLINICAL IMPLICATIONS:  Physicians should consider side-effect profiles and the costs of potential side-effects when selecting among pharmacologic agents for DVT prevention.

DISCLOSURE:  Andrew Shorr, None.

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543